Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Capital Expenditures: 2024-2025

Historic Capital Expenditures for Silence Therapeutics (SLN) over the last 2 years, with Sep 2025 value amounting to $3,000.

  • Silence Therapeutics' Capital Expenditures fell 95.31% to $3,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $117,000, marking a year-over-year change of. This contributed to the annual value of $211,000 for FY2024, which is 276.79% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Capital Expenditures is $3,000, which was down 93.75% from $48,000 recorded in Q2 2025.
  • Over the past 5 years, Silence Therapeutics' Capital Expenditures peaked at $85,000 during Q2 2024, and registered a low of $3,000 during Q3 2025.
  • Moreover, its 2-year median value for Capital Expenditures was $55,000 (2024), whereas its average is $44,333.
  • Data for Silence Therapeutics' Capital Expenditures shows a maximum YoY crashed of 95.31% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Silence Therapeutics' Capital Expenditures stood at $62,000 in 2024, then slumped by 95.31% to $3,000 in 2025.
  • Its last three reported values are $3,000 in Q3 2025, $48,000 for Q2 2025, and $4,000 during Q1 2025.